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Factors associated with non-
initiation of latent tuberculosis 
treatment among healthcare 
workers with a positive interferon-
gamma releasing assay
Hyun Lee, Gun Woo Koo, Ji-Hee Min, Tai Sun Park, Dong Won Park, Ji-Yong Moon,  
Sang-Heon Kim, Tae Hyung Kim, Ho Joo Yoon & Jang Won Sohn
Despite widespread use of the interferon-gamma release assay for the diagnosis of latent tuberculosis 
infection (LTBI), the initiation rate of and factors associated with LTBI treatment among healthcare 
workers (HCWs) have not been studied in depth. The aim of this study was to evaluate the initiation 
rate of LTBI treatment and also to identify any factors associated with non-initiation of LTBI treatment 
among HCWs. A retrospective cohort study of 293 HCWs with LTBI was performed at a teaching hospital 
in Korea. LTBI was diagnosed using QuantiFERON-TB Gold In-Tube tests (Cellestis Ltd., Carnegie, VIC, 
Australia). Of the 293 HCWs with LTBI, 189 HCWs (64.5%) visited an outpatient clinic for a medical 
consultation regarding LTBI treatment. Of these, 128 (67.7%) consented to LTBI treatment for a 43.7% 
LTBI treatment initiation rate. Upon multivariable analysis, having a liver disease or currently taking 
hepatotoxic drugs (adjusted odds ratio [OR] = 12.03, 95% confidence interval [CI] = 3.12–46.35), 
being a physician (adjusted OR = 14.01, 95% CI = 2.82–69.74) and other patient-related HCWs 
(adjusted OR = 3.58, 95% CI = 1.46–8.78), and years of employment ≥20 years (adjusted OR = 4.77, 
95% CI = 1.74–13.12) were independent factors associated with the non-initiation of LTBI treatment. 
Upon bivariate multivariable analysis, while having a liver disease or currently taking hepatotoxic 
drugs (adjusted OR = 12.85, 95% CI = 3.06–55.92), being a physician (adjusted OR = 28.43, 95% 
CI = 4.78–169.28) and other patient-related HCWs (adjusted OR = 4.80, 95% CI = 1.56–14.74), and 
years of employment ≥20 years (adjusted OR = 4.55, 95% CI = 1.37–15.15) were factors associated 
with no outpatient clinic visit for a consultation of LTBI treatment, having a liver disease or currently 
taking hepatotoxic drugs (adjusted OR = 11.76, 95% CI = 2.68–51.73) and years of employment ≥20 
years (adjusted OR = 5.29, 95% CI = 1.38–20.19) were factors associated with refusal of LTBI treatment 
after a consultation. The overall initiation rate of LTBI treatment was suboptimal in HCWs with LTBI 
diagnosed using an interferon-gamma releasing assay. Having a liver disease or currently taking 
hepatotoxic drugs, being a physician and other patient-related HCWs, and years of employment ≥20 
years were associated with non-initiation of LTBI treatment.
Healthcare workers (HCWs) are at higher risk of M. tuberculosis infection due to their risk of occupational expo-
sure to patients with active pulmonary tuberculosis1,2. Worldwide, the latent tuberculosis infection (LTBI) rate 
among HCWs was reported to range from 4–64%; this rate varied widely according to the burden of the study 
population3,4. Recent studies have shown that the LTBI rate among HCWs in Korea, an intermediate-tuberculosis 
(TB) burden country, was from 15–37%5–10.
The successful treatment of LTBI among HCWs is important for two clinical reasons. First, it can prevent 
HCWs with LTBI from developing into active pulmonary TB, which could be transmitted to patients. Second, 
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treatment also improves the health of the HCWs themselves. Unfortunately, the LTBI treatment initiation rate has 
been suboptimal in most studies11–13, although a few have reported high rates14,15.
To enhance the treatment acceptance rate of LTBI, it is vital to identify some modifiable factors, such as the 
interference of prior bacilli Calmette-Guérin (BCG) vaccination, in the interpretation of the LTBI diagnosis, 
which significantly affects the initiation rate of LTBI treatment among HCWs13,15. According to previous studies, 
HCWs diagnosed with LTBI via a positive tuberculin skin test (TST) who had received a prior BCG vaccination 
were more likely to refuse LTBI treatment13,15.
Because the interferon gamma releasing assay (IGRA), a novel diagnostic method for LTBI, is not affected by 
prior BCG vaccination, IGRA is now preferred over the TST to test people who have had a prior BCG vaccina-
tion16. In addition, in an era of IGRA-based LTBI diagnoses, the initiation rate of and factors associated with the 
acceptance of LTBI treatment among HCWs might be different from those performed for LTBI diagnoses based 
upon the TST. However, few studies are available regarding these issues. Therefore, we aimed to evaluate the ini-
tiation rate of and factors associated with LTBI treatment initiation among HCWs.
Results
Study population. The baseline characteristics of the study population are summarized in Table 1. The 
median age was 46 years and 61.4% (180/293) were female. There were 258 patient-related HCWs including 19 
physicians (6.5%), 53 nurses (18.1%), 186 other HCWs (63.5%), and 35 patient-unrelated HCWs (11.9%). The 
years of employment were as follows: <10 years (n = 57, 19.4%), 10–20 years (n = 67, 22.9%), and ≥20 years 
(n = 169, 57.7%). The common comorbidities were chronic liver diseases or currently taking hepatotoxic drugs 
(n = 30, 10.2%), hypertension (n = 22, 7.5%), diabetes mellitus (n = 20, 6.8%), and malignancy (n = 10, 3.4%). In 
addition, 34.5% of the HCWs had a previous history of working in a high-risk department. None of the HCWs 
tested was positive for human immunodeficiency virus infection.
The overall initiation rate of LTBI treatment among HCWs with a positive QFT-GIT and the 
acceptance rate of LTBI treatment among the HCWs who visited outpatient clinics. As shown 
in Fig. 1, the overall initiation rate of LTBI treatment was 43.7% (128/293). Of the 293 HCWs with a positive 
QFT-GIT, 189 (64.5%) visited an outpatient clinic for a consultation regarding LTBI treatment. Of these, 67.7% of 
HCWs (128/189) consented to LTBI treatment, while 32.3% (61/189) refused the LTBI treatment.
Total (N = 293)
Age, years 46 (41–52)
  21–30 21 (7.2)
  31–40 44 (15.0)
  41–50 129 (44.0)
  >50 99 (33.8)
Sex, female 180 (61.4)
Occupation
  Patient-unrelated HCWs* 35 (11.9)
Patient-related HCWs
  Physicians 19 (6.5)
  Nurses 53 (18.1)
  Others† 186 (63.5)
Years of employment, years
  <10 57 (19.4)
  10–20 67 (22.9)
  >20 years 169 (57.7)
Comorbidities
  Liver diseases or currently taking hepatotoxic drugs 30 (10.2)
  Hypertension 22 (7.5)
  Diabetes mellitus 20 (6.8)
  Malignancy 10 (3.4)
  Immunocompromised 9 (3.1)
  Others 19 (6.5)
A previous history of working in a high-risk department‡
  Yes 101 (34.5)
  No 192 (65.5)
Table 1. Baseline characteristics of the study population. Data are presented as median (interquartile range) 
or number (%). *Patient-unrelated HCWs included administrative staff, cooks, and cleaning staff. †Others 
included radiology technicians, laboratory technicians, physical therapists, and medical technicians. ‡High-risk 
departments included internal medicine wards and outpatient clinics, isolation wards, emergency department, 
intensive care units, clinical laboratory, and infection-control units. HCW, heath care worker.
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Factors associated with non-initiation of LTBI treatment (no outpatient clinic visit or refusal of 
LTBI treatment) among HCWs with a positive QFT-GIT. The univariable analysis revealed that HCWs 
in their thirties were 2.74 (95% confidence interval [CI] = 1.01–7.40) times less likely to receive LTBI treatment 
compared to workers in their twenties. Physicians were 7.11 (95% CI = 1.75–28.93) times less likely to receive 
LTBI treatment than patient-unrelated HCWs. HCWs with a liver disease or currently taking hepatotoxic drugs 
were 8.15 (95% CI = 2.41–27.53) times less likely to receive LTBI treatment than those without a liver disease 
or currently taking hepatotoxic drugs. HCWs who had been employed for more than 20 years were 2.31 (95% 
CI = 1.26–4.26) times less likely to receive LTBI treatment compared to those who had worked for less than 10 
years. In the multivariable analysis, HCWs with a liver disease or currently taking hepatotoxic drugs were 12.03 
(95% CI = 3.12–46.35) times less likely to receive LTBI treatment than those without a liver disease or currently 
taking hepatotoxic drugs. Physicians and patient-related other HCWs were found to be 14.01 (95 CI = 2.82–
69.74) and 3.58 (95% CI = 1.46–8.78) times less likely to receive LTBI treatment compared to patient-unrelated 
HCWs, respectively. In addition, HCWs with years of employment >20 years were 4.77 (95% CI = 1.74–13.12) 
times less likely to receive LTBI treatment compared to those with years of employment <10 years (Table 2).
Factors associated with no outpatient clinic visit for a consultation of LTBI treatment. The 
bivariate univariable analysis revealed that having a liver disease or currently taking hepatotoxic drugs (unad-
justed odds ratio [OR] = 8.14, 95% CI = 2.32–28.63) and being a physician (unadjusted OR = 14.29, 95% 
CI = 3.16–64.61) were significantly associated with no outpatient clinic visit for a consultation of LTBI treat-
ment. The bivariate multivariable analysis revealed that compared to the HCWs without a liver disease or cur-
rently taking hepatotoxic drugs, those with a liver disease or currently taking hepatotoxic drugs were 12.85 (95% 
CI = 3.06–55.92) times less likely to visit an outpatient clinic for a consultation of LTBI treatment. Compared 
to patient-unrelated HCWs, physicians or other patient-related HCWs were 28.43 (95% CI = 4.78–169.28) and 
4.80 (95% CI = 1.56–14.74) times less likely to visit an outpatient clinic for a consultation of LTBI treatment. In 
addition, years of employment ≥20 years (unadjusted OR = 4.55, 95% CI = 1.37–15.15) were associated with no 
outpatient clinic visit for a consultation of LTBI treatment (Table 3).
Factors associated with refusal of LTBI treatment among the HCWs who visited an outpa-
tient clinic for a consultation of LTBI treatment. In the univariable bivariate analysis, age group >50 
years (unadjusted OR = 4.85, 95% CI = 1.01–23.32), having a liver disease or currently taking hepatotoxic drugs 
(unadjusted OR = 8.17, 95% CI = 2.16–30.91), years of employment ≥20 years (unadjusted OR = 4.02, 95% 
CI = 1.55–10.38) were associated with refusal of LTBI treatment among HCWs who visited an outpatient clinic 
for a consultation of LTBI treatment. In the multivariable bivariate analysis, having a liver disease or currently 
taking hepatotoxic drugs was significantly associated with refusal of LTBI treatment among HCWs who visited 
an outpatient clinic for a consultation of LTBI treatment (adjusted OR = 11.76, 95% CI = 2.68–51.73). Being a 
HCW who worked for at least 20 years was associated with refusal of LTBI treatment (adjusted OR = 5.29, 95% 
CI = 1.38–20.19) (Table 3).
Discussion
The present study evaluated factors associated with non-initiation of LTBI treatment among HCWs in a teaching 
hospital. Of the 293 HCWs with LTBI, about two-thirds sought medical consultation for LTBI treatment, and 
another two-thirds of these consented to the LTBI treatment. This study revealed that having a liver disease or 
currently taking hepatotoxic drugs, being a physician and other patient-related HCWs, and working in healthcare 
for more than 20 years were independent factors associated with non-initiation of LTBI treatment.
Figure 1. Flow chart of the study population. HCW, healthcare worker; QFT-GIT, QuantiFERON-TB In-
Tube Gold test; TB, tuberculosis; LTBI, latent tuberculosis infection.
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Before the introduction of IGRA, TST was the only modality to diagnose LTBI. However, since IGRA is 
known to be more specific, better correlated with the burden of TB exposure and less influenced by a prior 
BCG vaccination, non-tuberculous infection, and immunosuppressive treatment or immunocompromised status 
compared to TST17–19, IGRA is now widely used in many countries worldwide20. In the era of TST-based LTBI 
diagnosis, the initiation rates of LTBI treatment among HCWs varied considerably according to the study pop-
ulation with LTBI, which ranged between 47–98%12,15,21,22. While some previous studies have evaluated the use 
of IGRA in the diagnosis of LTBI among HCWs, these studies have focused on a comparison of the performance 
between IGRA and TST5,6. Thus, few data currently exist regarding the rate of LTBI treatment among HCWs who 
are diagnosed of LTBI with IGRA.
Previous studies have revealed that prior BCG vaccination was significantly associated with non-initiation 
of LTBI treatment among HCWs with a positive TST; a substantial proportion of HCWs with positive TSTs was 
regarded by physicians as having false-positive results13. Moreover, the HCWs who had received prior vacci-
nations were also more likely to refuse LTBI treatment13,15. The HCWs who refused LTBI treatment may have 
regarded their positive TST results as false-positive due to their prior BCG vaccination, or they might have had 
the misconception that a prior BCG vaccination would prevent LTBI from progressing to an active disease state13. 
In this view, IGRA has an advantage over TST in that it reduces the range of LTBI diagnoses arising from varied 
TST interpretations.
However, surprisingly, despite the aforementioned potential advantage of IGRA over TST, the initiation rate of 
LTBI treatment in this study was about 45% which is relatively lower compared to that in previous studies, where 
the LTBI was diagnosed using TST. Another study which evaluated factors associated with positive IGRA among 
HCWs in Korea revealed similar results8. However, since the previous study and our study did not compare the 
initiation rate of LTBI treatment between HCWs diagnosed of LTBI by IGRA versus those diagnosed by TST, 
future studies are needed to confirm whether diagnostic modality can affect the initiation rate of LTBI treatment.
Total 
(N = 293)
Initiation of LTBI 
treatment
Unadjusted OR (95% CI) Adjusted OR (95% CI)
Yes 
(n = 128)
No 
(n = 165)
Age group, years
  21–30 25 (8.5) 15 (11.7) 10 (6.1) Reference Reference
  31–40 48 (16.4) 17 (13.3) 31 (18.8) 2.74 (1.01–7.40) 1.58 (0.41–6.11)
  41–50 131 (44.7) 62 (48.4) 69 (41.8) 1.67 (0.7–3.99) 0.60 (0.16–2.26)
  >50 89 (30.4) 34 (26.6) 55 (33.3) 2.43 (0.98–6.01) 0.65 (0.16–2.64)
Sex
  Male 113 (38.6) 45 (35.2) 68 (41.2) Reference Reference
  Female 180 (61.4) 83 (64.8) 97 (58.8) 0.77 (0.48–1.25) 0.72 (0.40–1.28)
Occupation
  Patient-unrelated HCWs* 35 (11.9) 20 (15.6) 15 (9.1) Reference Reference
   Patient-related HCWs
     Physician 19 (6.5) 3 (2.3) 16 (9.7) 7.11 (1.75–28.93) 14.01 (2.82–69.74)
     Nurse 53 (18.1) 27 (21.1) 26 (15.8) 1.28 (0.54–3.03) 3.04 (1.0–9.27)
     Others† 186 (63.5) 78 (60.9) 108 (65.5) 1.85 (0.89–3.83) 3.58 (1.46–8.78)
Comorbidities
  Liver disease or currently taking hepatotoxic drugs 30 (10.2) 3 (2.3) 27 (16.4) 8.15 (2.41–27.53) 12.03 (3.12–46.35)
  Immunocompromised 9 (3.1) 3 (2.3) 6 (3.6) 1.57 (0.39–6.41) 1.84 (0.38–9.0)
  Hypertension 22 (7.5) 8 (6.3) 14 (8.5) 1.39 (0.56–3.42) 1.33 (0.45–3.94)
  Malignancy 10 (3.4) 6 (4.7) 4 (2.4) 0.51 (0.14–1.83) 0.32 (0.07–1.45)
  Diabetes mellitus 20 (6.8) 10 (7.8) 10 (6.1) 0.76 (0.31–1.89) 0.43 (0.14–1.29)
  Others 19 (6.5) 6 (4.7) 13 (7.9) 1.74 (0.64–4.71) 1.75 (0.57–5.44)
Years of employment, years
  <10 57 (19.4) 33 (25.8) 24 (14.6) Reference Reference
  10–20 67 (22.9) 32 (25.0) 35 (21.2) 1.50 (0.74–3.06) 1.77 (0.63–4.95)
  ≥20 169 (57.7) 63 (49.2) 106 (64.2) 2.31 (1.26–4.26) 4.77 (1.74–13.12)
History of working in a high-risk department‡
  No 192 (65.5) 87 (68.0) 105 (63.6) Reference Reference
  Yes 101 (34.5) 41 (32.0) 60 (36.4) 1.21 (0.74–1.98) 1.18 (0.65–2.15)
Table 2. Unadjusted and adjusted odds ratios of the clinical variables associated with non-initiation of LTBI 
treatment among the HCWs with LTBI. *Patient-unrelated HCWs included administrative staff, cooks, and 
cleaning staff. †Others included radiology technicians, laboratory technicians, physical therapists, and medical 
technicians. ‡High-risk departments included internal medicine wards and outpatient clinics, isolation wards, 
emergency department, intensive care units, clinical laboratory, and infection-control units. HCW, healthcare 
worker; LTBI, latent tuberculosis infection; OR, odds ratio; CI, confidence interval.
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As shown in this study, non-initiation of LTBI treatment can be caused by “no outpatient clinical visit” and 
“treatment refusal”. Surprisingly, in this study, the major cause of non-initiation of treatment was “no outpatient 
visit” rather than “treatment refusal”; about one-third of the HCWs with LTBI did not visit an outpatient clinic 
for a medical consultation regarding LTBI treatment, which is significantly lower compared to a previous study 
in which 98% of HCWs with a positive TST consulted with physicians15. However, since we did not interview the 
HCWs who did not visit an outpatient clinic, we could not identify their specific reasons for not seeking an eval-
uation of their condition. Despite this limitation, we found that physicians are at the highest risk of not receiving 
a medical consultation. In this study, only 21% of physicians visited an outpatient clinic. However, the acceptance 
rate of LTBI treatment among the physicians who did visit an outpatient clinic was relatively high (75%) and was 
in agreement with the findings of a previous study23. The physicians’ busier schedules might have contributed to 
the lower outpatient clinic visit rate. In contrast, physicians are likely more knowledgeable about LTBI than other 
HCWs, which might have led to a higher acceptance rate of treatment.
In this study, a longer duration of employment in the healthcare field was significantly associated with both 
no outpatient clinic visit and refusal of LTBI treatment. However, the fact that clinicians and healthcare workers 
exposed for longer duration (i.e., working for longer) refused treatment for LTBI is not surprising, considering 
that the predictive value of IGRA to the development of active TB is not clear and the known hepatotoxic effects 
of LTBI treatment win those older than 35 years is also a hindrance24. Another important factor associated with 
both no outpatient clinic visit and refusal of LTBI treatment in this study was having a liver disease or currently 
taking hepatotoxic drugs; this finding could be explained by the results of a previous study, which found that 
“believing that taking medicine would be problematic” is associated with non-acceptance of LTBI treatment initi-
ation11. Thus, HCWs with a chronic liver disease or who were currently being prescribed hepatotoxic drugs might 
have refused LTBI treatment due to a fear of the liver toxicity often associated with LTBI treatment. The current 
Visit outpatient clinics for a consultation of LTBI treatment Refusal of LTBI treatment
Visit 
(n = 189)
No visit 
(n = 104)
Unadjusted OR 
(95% CI)
Adjusted OR (95% 
CI)
Acceptance 
(n = 128)
Refusal 
(n = 61)
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Age group
  21–30 years 17 (9.0) 8 (7.7) Reference Reference 15 (11.7) 2 (3.3) Reference Reference
  31–40 years 27 (14.3) 21 (20.2) 2.32 (0.79–6.75) 1.03 (0.22–4.87) 17 (13.3) 10 (16.4) 4.41 (0.83–23.42) 4.01 (0.51–31.79)
  41–50 years 89 (47.1) 42 (40.4) 1.27 (0.49–3.26) 0.48 (0.10–2.23) 62 (48.4) 27 (44.2) 3.27 (0.70–15.28) 0.92 (0.12–7.03)
  >50 years 56 (29.6) 33 (31.7) 1.82 (0.68–4.86) 0.50 (0.10–2.57) 34 (26.6) 22 (36.1) 4.85 (1.01–23.32) 1.07 (0.55–8.63)
Sex
  Male 64 (33.9) 49 (47.1) Reference Reference 45 (35.2) 19 (31.1) Reference Reference
  Female 125 (66.1) 55 (52.9) 0.61 (0.36–1.03) 0.53 0.28–1.02) 83 (64.8) 42 (68.9) 1.20 (0.62–2.30) 1.16 (0.55–2.48)
Comorbidities
  Liver disease or currently 
taking hepatotoxic drugs 13 (6.88) 17 (16.4) 8.14 (2.32–28.63) 12.85 (3.06–55.92) 3 (2.3) 10 (16.4) 8.17 (2.16–30.91) 11.76 (2.68–51.73)
  Immunocompromised 6 (3.2) 3 (2.9) 1.24 (0.24–6.26) 1.30 (0.19–9.02) 3 (2.3) 3 (4.9) 2.15 (0.42–11.0) 2.58 (0.44–15.30)
  Hypertension 11 (5.8) 11 (10.6) 1.77 (0.69–4.59) 1.71 (0.53–5.53) 8 (6.3) 3 (4.9) 0.78 (0.20–3.03) 0.79 (0.18–3.57)
  Malignancy 8 (4.2) 2 (1.9) 0.40 (0.08–2.02) 0.33 (0.05–2.02) 6 (4.7) 2 (3.3) 0.69 (0.14–3.52) 0.32 (0.05–2.13)
  Diabetes mellitus 14 (7.4) 6 (5.8) 0.72 (0.25–2.06) 0.36 (0.10–1.32) 10 (7.8) 4 (6.6) 0.83 (0.25–2.75) 0.50 (0.12–2.05)
  Others 7 (3.7) 12 (11.5) 2.65 (0.96–7.33) 3.14 (0.97–10.16) 6 (4.7) 1 (1.6) 0.34 (0.04–2.88) 0.24 (0.02–2.31)
Occupation
  Patient-unrelated HCWs* 28 (14.8) 7 (6.7) Reference Reference 20 (15.6) 8 (13.1) Reference Reference
   Patient-related HCWs
     Physician 4 (2.1) 15 (14.4) 14.29 (3.16–64.61) 28.43 (4.78–169.28) 3 (2.4) 1 (1.6) 0.83 (0.08–9.25) 1.56 (0.12–7.03)
     Nurse 39 (20.6) 14 (13.5) 1.48 (0.51–4.34) 3.48 (0.88–13.80) 27 (21.1) 12 (19.7) 1.11 (0.38–3.22) 2.78 (0.74–10.44)
     Others† 118 (62.5) 68 (65.4) 2.49 (0.99–6.25) 4.80 (1.56–14.74) 78 (60.9) 40 (65.6) 1.28 (0.52–3.17) 2.70 (0.94–7.75)
Years of employment, years
  <10 39 (20.6) 18 (17.3) Reference Reference 33 (25.8) 6 (9.8) Reference Reference
  ≥10 but <20 41 (21.7) 26 (25.0) 1.49 (0.69–3.23) 2.38 (0.71–7.92) 32 (25.0) 9 (14.8) 1.55 (0.49–4.85) 0.95 (0.22–4.01)
  ≥20 109 (57.7) 60 (57.7) 1.75 (0.89–3.43) 4.55 (1.37–15.15) 63 (49.2) 46 (75.4) 4.02 (1.55–10.38) 5.29 (1.38–20.19)
History of working in a high-risk department‡
  No 129 (68.3) 63 (60.6) Reference Reference 87 (68.0) 42 (68.9) Reference Reference
  Yes 60 (31.7) 41 (39.4) 1.38 (0.80–2.37) 1.54 (0.79–3.0) 41 (32.0) 19 (31.1) 0.96 (0.50–1.85) 0.77 (0.36–1.68)
Table 3. Bivariate analyses of factors associated with non-initiation of LTBI treatment (no outpatient clinic 
visit and refusal of LTBI treatment) according among the HCWs with LTBI. *Patient-unrelated HCWs included 
administrative staff, cooks and cleaning staff. †Others included radiology technicians, laboratory technicians, 
physical therapists, and medical technicians. ‡High-risk departments included internal medicine wards and 
outpatient clinics, isolation wards, the emergency department, intensive care units, the clinical laboratory, 
and infection-control units. HCW, healthcare worker; LTBI, latent tuberculosis infection; OR, odds ratio; CI, 
confidence interval.
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standard or recommended anti-TB drug for LTBI for patients with a liver disease or those receiving hepatotoxic 
drugs has not been well established. Because first line anti-TB drugs are hepatotoxic and increase the risk of liver 
failure in these patients, a careful clinical judgement is necessary to ensure that the benefit of LTBI treatment out-
weighs the risks24. In addition, upon a clinical decision to treat LTBI, testing baseline liver function and regular 
follow-up is strongly encouraged to monitor hepatotoxicity24.
This study had several limitations. It was performed at a single university hospital in Korea. Since various 
factors, including different types of stigmas, can affect the acceptance of LTBI treatment in different ethnicities 
and populations, our findings might not be generalizable to HCWs in other countries. Second, we only included 
workers’ years of employment at our institution. As a result, HCWs who had been employed at other institutions 
before working at our institution would have been classified as having erroneously low years of employment. 
Third, we did not assess previous history of BCG vaccination of HCWs, which have been useful to assess it as 
a potential factor for non-initiation of LTBI treatment. Fourth, some of the 95% CIs for the results on factors 
associated non-initiation of LTBI treatment were quite wide probably due to relatively small number of these 
factors. Fifth, since we did not perform in-depth interviews with the HCWs who did not visit an outpatient clinic 
or who refused LTBI treatment, we could not identify specific reasons for non-initiation of LTBI treatment in 
at-risk HCWs. Thus, further studies that include interviews will be needed to determine some of these modifiable 
factors.
In conclusion, our study found that the initiation rate of LTBI treatment was suboptimal in HCWs with LTBI 
diagnosed using QFT-GIT; about one-third of HCWs with LTBI did not visit an outpatient clinic for a consulta-
tion regarding this condition. In addition, one-third of those who visited an outpatient clinic refused LTBI treat-
ment. Having a liver disease or currently taking hepatotoxic drugs, being a physician and other patient-related 
HCWs, and having more than 20 years of employment were factors that were independently associated with 
non-initiation of LTBI treatment.
Methods
Study design and population. A retrospective cohort study to assess factors associated with non-initiation 
of LTBI treatment in HCWs positive for LTBI was conducted at a single university hospital between November 
2016 and March 2017. During the study period, QuantiFERON-TB Gold In-Tube tests (QFT-GIT; Cellestis Ltd., 
Carnegie, VIC, Australia) were performed for 1,213 HCWs to screen for LTBI and were positive in 332 (27.4%) 
participants.
We enrolled 293 HCWs but excluded 39 who had undergone previous TB treatment (n = 37), had ever 
received LTBI treatment (n = 1) or were diagnosed with active pulmonary TB (n = 1) (Fig. 1).
The study protocol was approved by the Institutional Review Board of Hanyang University Hospital (IRB 
number 2017-02-018). All data were anonymized before analysis and informed consent from the study partici-
pants was waived due to the retrospective nature of this study.
In-hospital protocol for the management of HCWs with positive QFT-GIT. All HCWs who were 
positive for QFT-GIT were recommended to visit an outpatient clinic of four respiratory physicians (D.W.P., 
S.-H.K., H.J.Y., and J.W.S.) in our institution via a standardized short message service, informing the HCW who 
received the message is needed to visit an outpatient clinic for a consultation regarding LTBI treatment. If a HCW 
with a positive QFT-GIT did not visit an outpatient clinic, the same message was sent to the HCW three times 
over three months at intervals of one month. When HCWs with a positive QFT-GIT visited an outpatient clinic, 
detailed information regarding the presence of respiratory symptoms (cough, sputum, hemoptysis, and dyspnea) 
and previous treatment for pulmonary TB and LTBI treatment were performed. Those with lesions suspicious 
of active pulmonary TB visible on chest X-rays underwent further studies to evaluate the presence of active 
pulmonary TB (at least two sputum acid fast stain and culture with one sputum polymerase chain reaction for 
the detection of M. tuberculosis). HCWs who were positive for one of these tests were regarded as having active 
pulmonary TB. Despite negative results for the above-mentioned tests, active pulmonary TB was diagnosed in 
HCWs when chest X-ray findings suggestive of active pulmonary TB were noticed and clinical signs were com-
patible with active pulmonary TB. When active pulmonary TB had been excluded, all HCWs with a positive 
QFT-GIT who visited an outpatient clinic were encouraged to receive LTBI treatment. The information whether 
a QFT-GIT positive HCW consent to or refuse LTBI treatment after consultation were all recorded in the medical 
chart according to in-hospital infection prevention and control guideline.
Performance and interpretation of QFT-GIT. Two-staged QFT-GIT were performed according to the 
manufacturer’s instructions. One-milliliter aliquots of blood were drawn directly into three evacuated blood col-
lection tubes: one containing heparin only (negative control), one with T cell mitogen (positive control) and one 
containing M. tuberculosis-specific antigens, including early secreted antigenic target 6, culture filtrate protein 10 
and TB7.7 (TB-antigen tube). After overnight incubation, 200 ul of plasma were removed from each tube, and 
the concentration of interferon-gamma (IFN-γ) was measured using an enzyme-linked immunosorbent assay. A 
positive response was defined as an antigen-nil IFN-γ concentration ≥0.35 IU/ml5,25.
Measures. At the time of LTBI screening, according to in-hospital infection prevention and control guideline, 
information on age, gender, type of occupation, comorbidities, hospital department, years of employment at our 
institution, and cellular phone number were collected using a standardized questionnaire. For the study pur-
pose, after approval of this study by ethics committee in our institution, we merged these data with the following 
data collected by chart review: the results of QFT-GIT, outpatient clinic visit, and acceptance or refusal of LTBI 
treatment.
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The HCWs’ occupations were classified as either patient-related, including physicians, nurses (nurses and 
nurses’ aides) and others (radiology technicians, laboratory technicians, physical therapists, and medical tech-
nicians) or patient-unrelated HCWs (administrative staff, cooks and cleaning staff) according to history of ever 
working. The hospital departments were divided into high-risk and low-risk departments according to their 
workers’ relationship with TB patient care. Accordingly, internal medicine wards and outpatient clinics, isolation 
wards, emergency department, intensive care units, clinical laboratory, and infection-control units were classified 
as high-risk departments; other departments without routine TB patients or specimen contact were classified as 
low-risk departments. Comorbidities included diabetes mellitus, hypertension, liver disease or currently taking 
hepatotoxic drugs (anti-fungal drugs, non-steroid anti-inflammatory drugs, lipid lowering agent, etc.), malig-
nancy, immunocompromised, and others. Based on the measures of the previous studies8–11, age was categorized 
into four groups by decade: 20 s (21–30 years), 30 s (31–40 years), 40 s (41–50 years), and older (>50 years), and 
years of employment were categorized into three groups of <10 years, ≥10 years but <20 years (termed “10–20 
years”), and ≥20 years8–10,26. LTBI was diagnosed in a patient who had a positive QFT-GIT.
Statistical analysis. Data are presented as the number and percentage for categorical variables and as 
the median and interquartile range (IQR) for continuous variables. Categorical variables were compared using 
Pearson’s chi-square test or Fisher’s exact test. Continuous variables were compared using the Mann-Whitney U 
test because the assumption of normality was significant for these variables. To evaluate the factors associated 
with non-initiation of LTBI treatment (no outpatient clinic visit or refusal of LTBI treatment), a multivariable 
logistic regression analysis was performed. Considering non-initiation rate of LTBI treatment and our sample 
size (about 55%, n = 293), we hypothesized that nine factors can be enough for our study questions based on the 
study suggesting how many predictors can be derived from data when doing regression analysis27. Thus, a total of 
11 factors entered into the logistic regression model, which included age, sex, chronic liver disease or currently 
taking hepatotoxic drug, immunocompromised, hypertension, malignancy, diabetes mellitus, other comorbid-
ities, type of occupation, years of employment, and history of working in a high-risk department. We further 
performed bivariate analysis to evaluate the factors associated with no outpatient clinic visit and refusal of LTBI 
treatment. All tests were two-sided, and P-values < 0.05 were considered statistically significant. All statistical 
analyses were performed using R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria), the 
Statistical Package for the Social Sciences (SPSS) for Windows (version 24.0; IBM Corp., Armonk, NY, US), and 
STATA (version 15.0; Stata Corporation, College Station, TX, USA).
Data Availability
All data extracted in this study are included in this article.
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